Profile data is unavailable for this security.
About the company
IQVIA Holdings Inc. is a global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry. The Company operates through three segments: Technology & Analytics Solutions, Research & Development Solutions and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides critical information, technology solutions and real-world insights and services to the Company's life science clients. The Research & Development Solutions segment primarily serves biopharmaceutical customers, providing outsourced clinical research and clinical trial related services. The Contract Sales & Medical Solutions segment provides health care provider, including contract sales and patient engagement services to both biopharmaceutical clients and the broader healthcare market. The Company protects individual patient privacy. The Company conducts business in more than 100 countries.
- Revenue in USD (TTM)14.31bn
- Net income in USD1.18bn
- Incorporated2016
- Employees83.00k
- LocationIQVIA Holdings Inc4820 Emperor BlvdDURHAM 27703United StatesUSA
- Phone+1 (919) 998-2000
- Fax+1 (302) 636-5454
- Websitehttps://ir.iqvia.com/
Mergers & acquisitions
| Acquired company | IQV:NYQ since announced | Transaction value |
|---|---|---|
| Pharmaspectra LLC | -11.42% | -- |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Seagen Inc | 1.86bn | -636.77m | 22.73bn | 2.68k | -- | 8.04 | -- | 12.19 | -3.46 | -3.46 | 10.14 | 15.23 | 0.4908 | 1.42 | 4.27 | 696,864.70 | -16.76 | -5.22 | -20.63 | -6.00 | 79.16 | 87.67 | -34.16 | -9.78 | 3.30 | -142.61 | 0.00 | -- | -27.63 | 30.36 | -209.91 | -- | 13.46 | -- |
| Horizon Therapeutics PLC | 3.70bn | 574.26m | 23.76bn | 2.10k | 43.12 | 4.76 | 24.69 | 6.42 | 2.43 | 2.43 | 15.68 | 22.01 | 0.4198 | 4.31 | 5.21 | 1,958,455.00 | 6.51 | 3.93 | 7.21 | 4.64 | 75.12 | 71.37 | 15.51 | 10.98 | 3.74 | 9.49 | 0.3376 | 0.00 | 46.63 | 26.88 | 37.12 | -- | 37.25 | -- |
| Gartner Inc | 5.28bn | 760.34m | 27.82bn | 16.60k | 37.96 | -- | 29.12 | 5.27 | 9.27 | 9.27 | 64.37 | -0.8201 | 0.7807 | -- | 5.11 | 317,918.80 | 11.25 | 4.12 | 20.19 | 7.06 | 69.34 | 65.00 | 14.41 | 6.65 | -- | 15.86 | 1.03 | -- | 15.48 | 14.13 | 197.50 | 32.60 | 3.71 | -- |
| Alnylam Pharmaceuticals, Inc. | 960.92m | -1.18bn | 28.84bn | 1.67k | -- | -- | -- | 30.01 | -9.77 | -9.77 | 7.95 | -0.5499 | 0.2743 | 1.45 | 6.86 | 577,127.90 | -33.74 | -32.56 | -42.04 | -37.94 | 83.85 | -- | -123.02 | -223.64 | 3.33 | -2.76 | 1.07 | -- | 71.31 | 78.07 | 0.6358 | -- | 3.42 | -- |
| DuPont de Nemours Inc | 14.18bn | 1.16bn | 35.55bn | 28.00k | 31.27 | 1.43 | 14.27 | 2.51 | 2.29 | 3.63 | 27.84 | 50.15 | 0.3148 | 3.54 | 5.49 | 506,571.40 | 2.71 | -0.2227 | 3.11 | -0.2892 | 35.05 | 31.60 | 8.62 | -1.61 | 1.99 | 5.11 | 0.3173 | -- | 16.15 | -19.13 | 172.14 | -15.09 | -25.20 | -26.30 |
| Iqvia Holdings Inc | 14.31bn | 1.18bn | 40.44bn | 83.00k | 35.43 | 7.57 | 18.15 | 2.83 | 6.15 | 6.15 | 74.43 | 28.78 | 0.593 | -- | 5.76 | 181,101.30 | 4.94 | 1.77 | 6.25 | 2.14 | 34.72 | 34.30 | 8.34 | 3.64 | -- | 5.19 | 0.6986 | 0.00 | 22.14 | 15.28 | 246.24 | 68.08 | 31.30 | -- |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Sep 2022 | 20.47m | 11.02% |
| BlackRock Fund Advisorsas of 30 Sep 2022 | 10.29m | 5.54% |
| SSgA Funds Management, Inc.as of 30 Sep 2022 | 8.61m | 4.64% |
| AllianceBernstein LPas of 30 Sep 2022 | 5.16m | 2.78% |
| Geode Capital Management LLCas of 30 Sep 2022 | 3.63m | 1.96% |
| Farallon Capital Management LLCas of 30 Sep 2022 | 3.21m | 1.73% |
| Columbia Management Investment Advisers LLCas of 30 Sep 2022 | 3.20m | 1.72% |
| Canada Pension Plan Investment Boardas of 30 Sep 2022 | 3.09m | 1.67% |
| Lazard Asset Management LLCas of 30 Sep 2022 | 2.81m | 1.52% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 30 Sep 2022 | 2.50m | 1.35% |
